Sinusitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Sinusitis – Drugs In Development, 2024 report and make more profitable business decisions.
Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from a viral or bacterial infection or from an allergy. Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache, and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder such as HIV/AIDS or cystic fibrosis, and another allergic condition.
The Sinusitis drugs in development market research report provide comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Sinusitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 50 molecules, with 50 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Sinusitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Sinusitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Sinusitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncABT Innovations Inc
Amgen Inc
Amytrx Therapeutics Inc
Aodh Lifesciences Pvt Ltd
AstraZeneca Plc
Beijing FuKangren Bio-pharm Tech Co Ltd
Bio-Thera Solutions Ltd
Blue Water Biotech Inc
Celltrion Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Diceros Therapeutics Inc
FUJIFILM Toyama Chemical Co Ltd
Furen Pharmaceutical Group Co Ltd
GeneOne Life Science Inc
Genrix (Shanghai) Biopharmaceutical Co Ltd
GlycoMira Therapeutics Inc
GSK plc
Insmed Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
JSR Life Sciences LLC
KeyMed Biosciences Inc
Lanier Biotherapeutics Inc
LianBio
Luye Pharma Group Ltd
Lyra Therapeutics Inc
Maxwell Biosciences Inc
MD Healthcare Inc
OptiNose Inc
Oticara Inc
Pfizer Inc
Pleros Therapeutics Inc
ProclaRx LLC
Quorum Innovations LLC
Recce Pharmaceuticals Ltd
Regeneron Pharmaceuticals Inc
Sanofi
SaNOtize Research and Development Corp
Shandong Boan Biotechnology Co Ltd
Shanghai JMT-Bio Technology Co Ltd
Synermore Biologics Co Ltd
Trellis Bioscience LLC
Trove Therapeutics Inc
Upstream Bio Inc
Wuhan Yicheng Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Sinusitis reports